Perspectives and experiences of health care professionals and patients regarding treatments for type 2 diabetes

Canadian Pharmacists Journal

Volumn 147, Issue 1, 2014, Pages 45-54

  Gauthier, Bernard ^a   Singh, Sumeet R ^b   Virani, Adil ^c,d   Staples, Heidi ^b   Colbourne, Ann ^e  

^a PeerVision Inc   (Canada)

^b CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH   (Canada)

^c Lower Mainland Pharmacy Services   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e ALBERTA HEALTH SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INCRETIN; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DIABETIC PATIENT; DRUG EFFICACY; EDEMA; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HEALTH INSURANCE; HEART FAILURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT PREFERENCE; PERSONAL EXPERIENCE; PRESCRIPTION; WEIGHT GAIN;

EID: 84893517353     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.1177/1715163513506547     Document Type: Article

References (37)

1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes2013;37(Suppl 1):S1-S212. Available: http://guidelines.diabetes.ca/App_Themes/CDACPG/resources/cpg_2013_full_en.pdf (accessed July 30, 2013).
2. Inzucchi SE,Bergenstal RM,Buse JB, et al.Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia. 2012;55:1577-96.
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet. 1998;352 (9131): 854-65.
4. Turner RC,Cull CA,Frighi V,Holman RR.Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49).JAMA. 1999;281:2005-12.
5. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London (UK): Royal College of Physicians; 2008. Available:www.nice.org.uk/nicemedia/pdf/CG66diabetesfullguideline.pdf (accessed July 30, 2013).
6. Canadian Agency for Drugs and Technologies in Health. Current utilization of second- and third-line therapies in patients with type 2 diabetes. Ottawa (ON): The Agency; 2010. (Optimal therapy report; vol. 4no. 3.) Available: www.cadth.ca/media/pdf/C1110-CU-Report-2nd-3rd-Line-Agents-final-e.pdf (accessed July 30, 2013).
7. Agarwal G,Nair K,Cosby J, et al.GPs' approach to insulin prescribing in older patients: a qualitative study.Br J Gen Pract. 2008;58:569-75.
8. Hayes RP,Bowman L,Monahan PO, et al.Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance.Diabetes Educ. 2006;32:404-14.
9. Nair KM,Levine MAH,Lohfeld LH,Gerstein HC."I take what I think works for me": a qualitative study to explore patient perception of diabetes treatment benefits and risks.Can J Clin Pharmacol. 2007;14 (2): e251-9.
10. Hayes RP,Fitzgerald JT,Jacober SJ.Primary care physician beliefs about insulin initiation in patients with type 2 diabetes.Int J Clin Pract. 2008;62 (6): 860-8.
11. Larkin ME,Capasso VA,Chen CL, et al.Measuring psychological insulin resistance: barriers to insulin use.Diabetes Educ. 2008;34 (3): 511-7.
12. Lawton J,Peel E,Parry O,Douglas M.Patients' perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study.Diabetes Med. 2008;25 (4): 491-5.
13. Cefalu WT,Mathieu C,Davidson J, et al.Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study.Diabetes Technol Ther. 2008;10:25-38.
14. Tjia J,Givens JL,Karlawish JH,Okoli-Umeweni A,Barg FK.Beneath the surface: discovering the unvoiced concerns of older adults with type 2 diabetes mellitus.Health Educ Res. 2008;23 (1): 40-52.
15. JeavonsDHunginAPCornfordCS. Patients with poorly controlled diabetes in primary care: healthcare clinicians' beliefs and attitudes. Postgrad Med J2006;82(967):347-50. Available: www.pubmedcentral.nih.gov/picrender.fcgi?artid=2563795&blobtype=pdf (accessed Nov. 8, 2012).
16. Lai WA,Lew-Ting CY,Chie WC.How diabetic patients think about and manage their illness in Taiwan.Diabetes Med. 2005;22 (3): 286-92.
17. Bonneville M,Colgin J,Nalesnick JA,Perez J,Wentz L.Patient perceptions of prandial oral therapy for type 2 diabetes.Diabetes Educ. 2001;27:669-77.
18. Huang ES,Brown SE,Thakur N, et al.Racial/ethnic differences in concerns about current and future medications among patients with type 2 diabetes.Diabetes Care. 2009;32:311-6.
19. Canadian Agency for Drugs and Technologies in Health. Current practice analysis of health care providers and patients: second-line therapy for patients with type 2 diabetes inadequately controlled on metformin. Ottawa (ON): The Agency; 2010 Mar. (Optimal therapy report; vol. 4no. 4.) Available: www.cadth.ca/media/compus/pdf/C1110_Current_Practice_Report_final.pdf. Accessed July 15, 2013.
20. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. Tri-Council policy statement: ethical conduct for research involving humans, 1998 (with 2000, 2002, 2005 amendments). Ottawa (ON): Interagency Secretariat on Research Ethics; 2005. Available: www.pre.ethics.gc.ca/eng/archives/tcps-eptc/Default/ (accessed Nov. 8, 2012).
21. MorganSRaymondCMooneyDMartinD. The Canadian Rx atlas. 2nd ed.Vancouver (BC): UBC Centre for Health Services and Policy Research; 2008. Available: www.chspr.ubc.ca/pubs/atlas/canadian-rx-atlas-2nd-edition (accessed Nov. 8, 2012).
22. Utilization of oral antiglycemics in Canada. Ottawa (ON): Brogan, Inc.; 2008:.
23. PsatyBMFurbergCD.The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med2007;357(1):67-9. Available: www.nejm.org/doi/full/10.1056/NEJMe078116 (accessed Nov. 5, 2012).
24. Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med. 2007;356 (24): 2457-71.
25. WoodcockJ, US Food and Drug Administration, Center for Drug Evaluation and Research. Letter to: NDA 021071. Decision on continued marketing of rosiglitazone (Avandia, Avandamet, Avandaryl). Silver Spring (MD): FDA; 2010Sep. 22. Available: www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf (accessed Nov. 5, 2012).
26. Avandia, Avandamet and Avandaryl-important new restrictions on the use of rosiglitazone products due to information on heart-related events. Ottawa (ON): Health Canada, Marketed Health Products Directorate. 2010Nov. 10. Available: www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/16117a-eng.php (accessed Nov. 5, 2012).
27. Colmers IN,Bowker SL,Majumdar SR,Johnson JA.Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.CMAJ. 2012;184 (12): E675-83.
28. Extended use of thiazolidinediones associated with increased bladder cancer risk in cohort study. ASCO Daily News. 2012Nov18. Presented at ASCO Annual 2012 Meeting; 2012 Jun 1-5; Chicago. Abstract 1503. Available: http://chicago2012.asco.org/ASCODailyNews/Abstract1503.aspx (accessed May 15, 2013).
29. KahnSEHaffnerSMHeiseMA. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med2006;355(23):2427-43. Available: http://content.nejm.org/cgi/reprint/355/23/2427.pdf (accessed May 15, 2013).
30. Bell DS.Beta-cell rejuvenation with thiazolidinediones.Am J Med. 2003;115:20S-3S.
31. Leiter LA.Can thiazolidinediones delay disease progression in type 2 diabetes?.Curr Med Res Opin. 2006;22:1193-201.
32. McIntoshBCameronCSinghS. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed treatment comparisons meta-analysis. Open Med2011;5(1). Available: www.openmedicine.ca/article/view/423/382 (accessed May 5, 2013).
33. Canadian Agency for Drugs and Technologies in Health. Type 2 diabetes-second- and third-line therapies. CADTH Optimal Therapy Newsletter. Ottawa (ON): The Agency; 2013. Available: www.cadth.ca/media/pdf/Type_2_Diabetes_2nd_and_3rd_Line_Therapies_Newsletter_e.pdf (accessed Aug. 20, 2013).
34. Canadian Agency for Drugs and Technologies in Health. Second-line pharmacotherapy for type 2 diabetes: update. CADTH Optimal Use Report2013;3:iss. 1A. Available: www.cadth.ca/media/pdf/OP0512_DiabetesUpdate_Second-line_e.pdf (accessed July 30, 2013).
35. Canadian Agency for Drugs and Technologies in Health. Third-line pharmacotherapy for type 2 diabetes: update. CADTH Optimal Use Report2013;3:iss. 1B. Available: www.cadth.ca/media/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf (accessed July 30, 2013).
36. Canadian Agency for Drugs and Technologies in Health. Optimal use recommendations for second-line and third-line pharmacotherapy for patients with type 2 diabetes. CADTH Optimal Use Report2013;3:iss. 1D. Available:www.cadth.ca/media/pdf/OP0512_Diabetes_RecsReport_2nd_3rd-line_e.pdf (accessed July 30, 2013).
37. Hepler CD,Strand LM.Opportunities and responsibilities in pharmaceutical care.Am J Hosp Pharm. 1990;47:533-43.